Followers | 507 |
Posts | 10138 |
Boards Moderated | 0 |
Alias Born | 04/28/2014 |
Wednesday, November 05, 2014 9:59:11 AM
bullish
$RGLS recent news/filings
## source: finance.yahoo.com
Wed, 05 Nov 2014 12:07:09 GMT ~ Q3 2014 Regulus Therapeutics Inc Earnings Release - After Market Close
read full: http://biz.yahoo.com/research/earncal/20141105.html?t=rgls
*********************************************************
Mon, 03 Nov 2014 22:01:52 GMT ~ Regulus Announces Closing of Public Offering of $103.5M of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
[at noodls] - LA JOLLA, Calif., Nov. 3, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today ...
read full: http://www.noodls.com/view/FC7FB74389DE616F3511E9EC80B38E536089B6F9
*********************************************************
Mon, 03 Nov 2014 21:05:00 GMT ~ Regulus Announces Closing of Public Offering of $103.5M of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
[PR Newswire] - LA JOLLA, Calif., Nov. 3, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the closing of its previously announced underwritten public offering of $103.5 million of shares of its common stock, including $13.5 million of shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, at a price to the public of $17.00 per share. Of the total 6,088,235 shares sold in the offering, 4,808,824 shares were sold by Regulus and 1,279,411 shares were sold by an existing stockholder of Regulus, Isis Pharmaceuticals, Inc. (ISIS). The net proceeds to Regulus from the offering are expected to be approximately $76.1 million after deducting underwriting discounts and commissions and other estimated offering expenses payable by Regulus. Regulus will not receive any proceeds from the sale of shares by Isis. Deutsche Bank Securities and BMO Capital Markets acted as joint book-running managers for the offering. Needham & Company, Wedbush PacGrow Life Sciences and FBR acted as co-managers.
read full: http://finance.yahoo.com/news/regulus-announces-closing-public-offering-210500751.html
*********************************************************
Mon, 03 Nov 2014 13:24:00 GMT ~ Super Important Biotech and Drug Stock Events for November
read full: http://www.thestreet.com/story/12937049/1/super-important-biotech-and-drug-stock-events-for-november.html?puc=yahoo&cm_ven=YAHOO
*********************************************************
Thu, 30 Oct 2014 21:13:02 GMT ~ Regulus Announces Timing for Third Quarter 2014 Financial Results Webcast and Conference Call
[at noodls] - LA JOLLA, Calif., Oct. 30, 2014 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, ...
read full: http://www.noodls.com/view/2788C0E533DA36291ADC25DD15A5A2F58F81C201
*********************************************************
$RGLS charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$RGLS company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/RGLS/company-info
Ticker: $RGLS
OTC Market Place: Not Available
CIK code: not found
Company name: Regulus Therapeutics Inc.
Incorporated In:
Business Description:
$RGLS share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$RGLS extra dd links
Company name: Regulus Therapeutics Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/RGLS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/RGLS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=RGLS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=RGLS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=RGLS+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/RGLS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/RGLS/news - http://finance.yahoo.com/q/h?s=RGLS+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/RGLS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/RGLS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/RGLS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/RGLS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/RGLS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/RGLS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/RGLS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/RGLS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=RGLS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/RGLS
DTCC (dtcc.com): http://search2.dtcc.com/?q=Regulus+Therapeutics+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Regulus+Therapeutics+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Regulus+Therapeutics+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/RGLS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/RGLS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/RGLS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/RGLS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/RGLS/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/RGLS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/RGLS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/RGLS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/RGLS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=RGLS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=RGLS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/RGLS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=RGLS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=RGLS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=RGLS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=RGLS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=RGLS+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/RGLS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=RGLS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/RGLS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=RGLS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/RGLS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/RGLS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/RGLS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/RGLS/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/RGLS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/RGLS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/RGLS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=RGLS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=RGLS
$RGLS DD Notes ~ http://www.ddnotesmaker.com/RGLS
Recent RGLS News
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/09/2024 08:54:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:27:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:15:41 PM
- Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates • PR Newswire (US) • 05/09/2024 08:05:00 PM
- Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) • PR Newswire (US) • 05/06/2024 12:00:00 PM
- Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series • PR Newswire (US) • 04/30/2024 12:00:00 PM
- Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates • PR Newswire (US) • 03/21/2024 08:05:00 PM
- Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity • PR Newswire (US) • 03/12/2024 10:32:00 AM
- Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) • PR Newswire (US) • 03/12/2024 10:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 01:24:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 01:23:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:08:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:04:34 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/12/2024 09:11:34 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/10/2024 05:15:20 AM
- Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) • PR Newswire (US) • 01/02/2024 09:05:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/27/2023 09:16:06 PM
- Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference • PR Newswire (US) • 11/22/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:39:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:15:35 PM
- Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates • PR Newswire (US) • 11/09/2023 09:05:00 PM
- Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) • PR Newswire (US) • 11/02/2023 12:00:00 PM
- Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) • PR Newswire (US) • 10/19/2023 12:00:00 PM
- Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) • PR Newswire (US) • 09/20/2023 11:00:00 AM
- Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) • PR Newswire (US) • 09/13/2023 12:00:00 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM